Detaljeret guide kommer snart
Vi arbejder på en omfattende uddannelsesguide til G6PD Deficiency Drug Risk. Kom snart tilbage for trin-for-trin forklaringer, formler, eksempler fra virkeligheden og eksperttips.
Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency, affecting approximately 400 million people worldwide, predominantly males due to its X-linked recessive inheritance pattern. G6PD is essential for the pentose phosphate pathway, which generates NADPH — the primary antioxidant defence inside red blood cells. Without adequate G6PD activity, red blood cells cannot neutralise reactive oxygen species (ROS) generated by oxidative stress from drugs, infections, or certain foods. This leads to oxidative damage of haemoglobin and the red cell membrane, forming Heinz bodies (denatured haemoglobin aggregates) that are recognised and removed by the spleen, causing haemolytic anaemia. The WHO classifies G6PD deficiency into five classes based on the degree of enzyme deficiency and clinical severity: Class I (severe deficiency with chronic non-spherocytic haemolytic anaemia), Class II (severe deficiency, <10% residual activity, intermittent acute haemolysis), Class III (moderate deficiency, 10–60% activity, haemolysis only with triggers), Class IV (mildly reduced or normal activity, clinically insignificant), and Class V (increased enzyme activity). The G6PD haemolysis risk calculator helps clinicians assess the likelihood of acute haemolysis based on a patient's known G6PD status and exposure to oxidative drugs or foods. The most common variants include G6PD A- (Africa), G6PD Mediterranean (Middle East and southern Europe), G6PD Canton (Southeast Asia), and G6PD Mahidol (Myanmar and Thailand).
G6PD Haemolysis Risk = f(WHO Class I–V, Drug Exposure, Infection Status, Fava Bean Ingestion) Where each variable represents a specific measurable quantity in the finance and lending domain. Substitute known values and solve for the unknown. For multi-step calculations, evaluate inner expressions first, then combine results using the standard order of operations.
- 1Confirm G6PD deficiency status through enzyme activity assay (fluorescent spot test or quantitative spectrophotometry).
- 2Classify the deficiency severity using WHO Class I–V based on residual enzyme activity and clinical history.
- 3Assess current exposure to known oxidative triggers: drugs (dapsone, primaquine, rasburicase, high-dose aspirin, nitrofurantoin, phenazopyridine), infections, or fava beans (favism).
- 4Evaluate haematological parameters: haemoglobin drop, reticulocyte count, LDH, bilirubin, and peripheral blood film for Heinz bodies and bite cells.
- 5Determine haemolysis risk level: low (Class IV/V, no exposure), moderate (Class III with mild oxidative trigger), or high (Class I/II with strong oxidative trigger).
- 6For high-risk situations, stop the offending agent, ensure adequate hydration, monitor for haemoglobinuria (dark urine), and assess need for blood transfusion.
- 7Provide patient education on drugs and foods to avoid long-term.
G6PD Mediterranean has <10% residual activity — very sensitive to primaquine
Class II G6PD deficiency with primaquine (an 8-aminoquinoline with strong oxidant potential) creates very high risk of acute haemolytic crisis.
Rasburicase generates H2O2 as a byproduct of uric acid metabolism
Rasburicase is contraindicated in all grades of G6PD deficiency. Use allopurinol or febuxostat instead for uric acid lowering.
Nitrofurantoin is on the avoid list for G6PD-deficient patients
Moderate G6PD deficiency with a mild-moderate oxidant drug warrants avoiding the drug and selecting a safer alternative.
Avoid aspirin (salicylates) in G6PD deficiency at high doses
Paracetamol is generally safe in G6PD deficiency at therapeutic doses. Aspirin at high doses (anti-inflammatory doses) should be avoided.
Mortgage lenders and loan officers use G6Pd Haemolysis Risk to structure repayment schedules, compare fixed versus adjustable rate options, and calculate total borrowing costs for residential and commercial real estate transactions across different term lengths.
Personal finance advisors apply G6Pd Haemolysis Risk when counseling clients on debt reduction strategies, comparing the mathematical benefit of accelerated payments against alternative investment returns to determine the optimal allocation of surplus cash flow.
Credit unions and community banks rely on G6Pd Haemolysis Risk to generate accurate Truth in Lending disclosures, ensure regulatory compliance with TILA and RESPA requirements, and provide borrowers with standardized cost comparisons across competing loan products.
Corporate treasury departments use G6Pd Haemolysis Risk to model the cost of revolving credit facilities, term loans, and commercial paper programs, optimizing the company's capital structure and minimizing weighted average cost of debt financing.
Zero or negative interest rate
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in g6pd haemolysis risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Balloon payment at maturity
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in g6pd haemolysis risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Variable rate mid-term adjustment
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in g6pd haemolysis risk calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Methylene Blue Contraindication
Methylene blue, used to treat methaemoglobinaemia, works through NADPH-dependent pathways. In G6PD-deficient patients, methylene blue is ineffective and can worsen haemolysis. Alternative treatments (ascorbic acid, exchange transfusion) should be used for methaemoglobinaemia in these patients.
| WHO Class | Enzyme Activity | Clinical Presentation | Common Variants |
|---|---|---|---|
| I | <1% (severe) | Chronic non-spherocytic haemolytic anaemia | G6PD Canton, G6PD Tripler |
| II | <10% (severe) | Acute haemolysis with oxidant exposure | G6PD Mediterranean, G6PD A- |
| III | 10–60% (moderate) | Haemolysis only with significant triggers | G6PD A-, G6PD Seattle |
| IV | 60–150% (normal) | Clinically insignificant | G6PD B (wildtype) |
| V | >150% (increased) | No haemolysis; enzyme overactivity | Rare variants |
Why are males more commonly affected by G6PD deficiency?
G6PD is encoded on the X chromosome. Males have only one X chromosome, so a single defective copy causes deficiency. Females have two X chromosomes and typically need both to be deficient (or to be very unfavourably lyonised) to exhibit significant symptoms, making them mostly carriers with variable enzyme activity.
What are the classic symptoms of a G6PD haemolytic episode?
In the context of G6Pd Haemolysis Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Which drugs must absolutely be avoided in G6PD deficiency?
In the context of G6Pd Haemolysis Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Can G6PD-deficient patients ever take primaquine?
In the context of G6Pd Haemolysis Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What is favism?
Favism is acute haemolytic anaemia triggered by ingestion of fava beans (broad beans) in G6PD-deficient individuals. It is most common in the Mediterranean variant (Class II). The oxidants vicine and convicine in fava beans overwhelm the deficient antioxidant system. Even inhalation of fava bean pollen can trigger crisis in very sensitive individuals.
How is G6PD deficiency diagnosed?
The WHO fluorescent spot test is the most widely used screening method: normal G6PD generates NADPH which fluoresces under UV light; a negative (non-fluorescent) spot indicates deficiency. Quantitative spectrophotometric assay measures actual enzyme activity and is used for confirmation and classification. Results must be interpreted carefully during or shortly after a haemolytic episode, when reticulocytosis can give falsely normal results.
Is G6PD deficiency protective against malaria?
In the context of G6Pd Haemolysis Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What neonatal complication is associated with G6PD deficiency?
In the context of G6Pd Haemolysis Risk, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Pro Tip
Carry a G6PD drug safety card. Many pharmacies and travel clinics can provide lists of safe and unsafe medications. Apps such as G6PD Deficiency Drug List provide real-time lookups of drug safety in G6PD deficiency.
Vidste du?
The geographic distribution of G6PD deficiency maps almost perfectly onto the historical range of malaria. The Sardinian population has one of the highest G6PD deficiency rates in Europe (up to 35% of males), corresponding to Sardinia's historically high malaria burden before the WHO eradication programme of the 1950s.